16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Few studies have focused on quality of life (QoL) after treatment of malignant pleural mesothelioma (MPM). There are still questions as to which surgical procedure, extrapleural pneumonectomy (EPP) or pleurectomy decortication (P/D) is most effective and results in better survival outcomes, involves fewer complications, and results in better QoL. Here we performed a literature review on MPM patients to assess and compare QoL changes after P/D and EPP.

          Methods

          Research articles concerning QoL after mesothelioma surgery were identified through May 2018 in Medline. For inclusion, studies were 1) cohort or randomized controlled trials (RCT) design, 2) included standardized QoL instruments, 3) reported QoL measurement after surgery, 4) described the type of surgery performed (EPP or P/D), 5) were written in English. Measures of lung function (FEV1, FVC) and measures from the EORTC-C30 were compared 6 months following surgery with preoperative values.

          Results

          QoL data was extracted from 17 articles (14 datasets), encompassing 659 patients (102 EPP, 432 P/D); the available evidence was of low quality. While two studies directly compared QoL between the two surgical procedures, additional data was available from one arm of two RCTs, as the RCTs were not comparing EPP and P/D. The remaining data was reported from observational studies. While QoL was still compromised 6 months following surgery, from the limited and low quality data available it would appear that P/D patients had better QoL than EPP patients across all measures. Physical function, social function and global health were better at follow-up for P/D than for EPP, while other indicators such as pain and cough were similar. Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC) were reported in one study only, and were higher at follow-up for P/D compared to EPP.

          Conclusions

          Although the existing evidence is limited and of low quality, it suggests that P/D patients have better QoL than EPP patients following surgery. QoL outcomes should be factored into the choice of surgical procedure for MPM patients, and the possible effects on lung function and QoL should be discussed with patients when presenting surgical treatment options.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          The European mesothelioma epidemic

          Projections for the period 1995–2029 suggest that the number of men dying from mesothelioma in Western Europe each year will almost double over the next 20 years, from 5000 in 1998 to about 9000 around 2018, and then decline, with a total of about a quarter of a million deaths over the next 35 years. The highest risk will be suffered by men born around 1945–50, of whom about 1 in 150 will die of mesothelioma. Asbestos use in Western Europe remained high until 1980, and substantial quantities are still used in several European countries. These projections are based on the fit of a simple age and birth cohort model to male pleural cancer mortality from 1970 to 1989 for six countries (Britain, France, Germany, Italy, The Netherlands and Switzerland) which together account for three-quarters of the population of Western Europe. The model was tested by comparing observed and predicted numbers of deaths for the period 1990–94. The ratio of mesothelioma to recorded pleural cancer mortality has been 1.6:1 in Britain but was assumed to be 1:1 in other countries. © 1999 Cancer Research Campaign
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Malignant pleural mesothelioma.

              Malignant pleural mesothelioma (MPM) is a deadly disease that occurs in 2,000 to 3,000 people each year in the United States. Although MPM is an extremely difficult disease to treat, with the median overall survival ranging between 9 and 17 months regardless of stage, there has been significant progress over the last few years that has reshaped the clinical landscape. This article will provide a comprehensive discussion of the latest developments in the treatment of MPM. We will provide an update of the major clinical trials that impact mesothelioma treatment in the resectable and unresectable settings, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. In addition, there are controversial issues, such as the role of extrapleural pneumonectomy, adjuvant radiotherapy, and use of intensity-modulated radiotherapy versus hemithoracic therapy that will also be addressed in this manuscript.
                Bookmark

                Author and article information

                Contributors
                Rschwartz3@northwell.edu
                wil.lieberman-cribbin@icahn.mssm.edu
                andrea.wolf@mountsinai.org
                raja.flores@mountsinai.org
                212-659-9590 , emanuela.taioli@mountsinai.org
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                29 November 2018
                29 November 2018
                2018
                : 18
                : 1188
                Affiliations
                [1 ]ISNI 0000 0001 2284 9943, GRID grid.257060.6, Department of Occupational Medicine, Epidemiology and Prevention, Northwell Health Physician Partners, , Hofstra Northwell School of Medicine, ; Great Neck, NY USA
                [2 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Institute for Translational Epidemiology and Department of Population Health Science and Policy, , Icahn School of Medicine at Mount Sinai, ; New York, NY USA
                [3 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Department of Thoracic Surgery, Mount Sinai Health System, , Icahn School of Medicine, ; New York, NY USA
                [4 ]ISNI 0000 0001 0670 2351, GRID grid.59734.3c, Tisch Cancer Institute, , Icahn School of Medicine at Mount Sinai, ; One Gustave L. Levy Place, Box 1133, New York, NY USA
                Author information
                http://orcid.org/0000-0001-6930-1635
                Article
                5064
                10.1186/s12885-018-5064-4
                6267825
                30497433
                eb252b34-0bdb-474f-b015-919ecd0789a5
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 23 May 2018
                : 7 November 2018
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Oncology & Radiotherapy
                outcomes,functional measures,cancer,surgical approach
                Oncology & Radiotherapy
                outcomes, functional measures, cancer, surgical approach

                Comments

                Comment on this article

                scite_
                33
                0
                24
                0
                Smart Citations
                33
                0
                24
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content616

                Cited by12

                Most referenced authors800